Phase II Study of CHOP[cyclophosphamide + vincristine + doxorubicin + prednisone]/Rituxan Plus VELCADE [bortezomib] in Mediastinal Large B-Cell Lymphoma.

Trial Profile

Phase II Study of CHOP[cyclophosphamide + vincristine + doxorubicin + prednisone]/Rituxan Plus VELCADE [bortezomib] in Mediastinal Large B-Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Bortezomib; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2009 Actual number of patients (3) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 06 Jun 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top